AstraZeneca acquires SixPeaks Bio

AstraZeneca has exercised an option to acquire SixPeaks Bio AG, an obesity drug startup, for a total consideration of USD 300 million. The consideration contains an upfront payment of USD 170 million, an additional fixed payment of USD 30 million and USD 100 million based on achievements of certain regulatory milestones. 

Lenz & Staehelin advised AstraZeneca in this transaction. The team was led by Tino Gaberthüel (M&A) and included Raphael Fries, Nils Maag (both M&A), Peter Ling (IP), Pascal Hinny, Franziska Stadtherr-Glättli (both Tax), Anja Affolter Marino and Julia van Heusden (both Employment).